InsiderTrades.com logo
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).

David Lamond Biography and Net Worth

Director of Applied Molecular Transport
  • LinkedIn
  • Phone
  • Email
  • Website


David A. Lamond joined our board of directors in September 2018. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the president, chief executive officer and chief investment officer of Lamond Capital Partners LLC. Mr. Lamond also is currently a member of the board of directors of Cortexyme, a biopharmaceutical company, and previously served on the board of Arrinex, a medical device company. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.

What is David Lamond's net worth?

The estimated net worth of David Lamond is at least $605,502.53 as of December 12th, 2023. Lamond owns 2,302,291 shares of Applied Molecular Transport stock worth more than $605,503 as of April 26th. This net worth approximation does not reflect any other investments that Lamond may own. Learn More about David Lamond's net worth.

How do I contact David Lamond?

The corporate mailing address for Lamond and other Applied Molecular Transport executives is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. Applied Molecular Transport can also be reached via phone at 650-392-0420 and via email at [email protected]. Learn More on David Lamond's contact information.

Has David Lamond been buying or selling shares of Applied Molecular Transport?

David Lamond has not been actively trading shares of Applied Molecular Transport in the last ninety days. Most recently, on Monday, May 23rd, David Lamond bought 33,500 shares of Applied Molecular Transport stock. The stock was acquired at an average cost of $3.26 per share, with a total value of $109,210.00. Following the completion of the transaction, the director now directly owns 1,077,519 shares of the company's stock, valued at $3,512,711.94. Learn More on David Lamond's trading history.

Who are Applied Molecular Transport's active insiders?

Applied Molecular Transport's insider roster includes Elizabeth Bhatt (Insider), Shawn Cross (CFO), Bittoo Kanwar (Insider), Helen Kim (Director), David Lamond (Director), Tahir Mahmood (CEO), Randall Mrsny (Insider), and Aaron VanDevender (Director). Learn More on Applied Molecular Transport's active insiders.

Are insiders buying or selling shares of Applied Molecular Transport?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 1,097,868 shares worth more than $176,549.76. The most recent insider tranaction occured on November, 22nd when CEO Shawn Cross sold 110,802 shares worth more than $17,728.32. Insiders at Applied Molecular Transport own 15.9% of the company. Learn More about insider trades at Applied Molecular Transport.

Information on this page was last updated on 11/22/2023.

David Lamond Insider Trading History at Applied Molecular Transport

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Buy33,500$3.26$109,210.001,077,519View SEC Filing Icon  
5/20/2022Buy33,000$3.08$101,640.001,044,019View SEC Filing Icon  
4/6/2021Buy25,000$42.00$1,050,000.00View SEC Filing Icon  
See Full Table

David Lamond Buying and Selling Activity at Applied Molecular Transport

This chart shows David Lamond's buying and selling at Applied Molecular Transport by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Molecular Transport Company Overview

Applied Molecular Transport logo
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
Read More

Today's Range

Now: $0.26
Low: $0.26
High: $0.26

50 Day Range

MA: $0.24
Low: $0.16
High: $0.31

2 Week Range

Now: $0.26
Low: $0.13
High: $0.84

Volume

N/A

Average Volume

470,969 shs

Market Capitalization

$10.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).